Arnob Banerjee MD
Hematologic Oncology
Director, Clinical Research, Oncology, Janssen Pharmaceuticals
Join to View Full Profile
1400 McKean RoadNorth Wales, PA 19477
Dr. Banerjee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2004 - 2009- University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2004
Columbia University Vagelos College of Physicians and SurgeonsClass of 2002
Certifications & Licensure
MD State Medical License 2010 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.Simon J Harrison, Cyrille Touzeau, Nicolas Kint, Katherine Li, Tamia Nguyen
The New England Journal of Medicine. 2025-02-13 - 2 citationsTalquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.Yael C Cohen, Hila Magen, Moshe Gatt, Michael Sebag, Kihyun Kim
The New England Journal of Medicine. 2025-01-09 - 7 citationsCorrelation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein
Blood. 2024-08-08
Abstracts/Posters
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...Arnob Banerjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...Arnob Banerjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple MyelomaJune 7th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
